Healthcare, Pharma & Life Sciences

Leo Cancer Care Launches Pediatric Program After First Upright Proton Treatments

Image
Leo Cancer Care Launches Pediatric Program After First Upright Proton Treatments

Boston – September 27, 2026 -- Leo Cancer Care has confirmed a dedicated pediatric program combining education, distraction and gamification technology, following the world's first pediatric treatments delivered on its upright Marie® positioning and imaging platform.

Stanford Medicine delivers first upright pediatric proton treatments in June 2026

Stanford Medicine treated the initial pediatric patients using the Mevion S250-FIT Proton Therapy System, which integrates Leo Cancer Care's Marie platform and RaySearch Laboratories' RayStation planning software. The early cases demonstrated that upright proton therapy is feasible across a wide pediatric age range, with anesthesia still available when clinically required.

Fuse Oncology to Showcase GE HealthCare iRT-S!GNAL Workflow at ASTRO 2026

Image
Fuse Oncology to Showcase GE HealthCare iRT-S!GNAL Workflow at ASTRO 2026

Boone, N.C. – September 27, 2026 -- Fuse Oncology plans to demonstrate a potential integration linking GE HealthCare's Intelligent Radiation Therapy (iRT) software to its S!GNAL charge capture platform at the ASTRO 2026 Annual Meeting, running September 27-29 in Boston at booth 2533.

Concept links radiation therapy workflow software directly to charge review

The showcased workflow would allow iRT to launch S!GNAL using existing patient information, giving radiation oncology teams a direct path from treatment coordination to targeted charge review without re-entering data across systems. The capability is described as planned for a future iRT release and is currently in development and evaluation, with no confirmed commercial availability date.

FUCASO Hits 95.9% Response Rate in China Real-World Myeloma Study

Shanghai – September 27, 2026 -- IASO Biotechnology's CAR-T therapy FUCASO achieved a 95.9% objective response rate and 77.2% complete/stringent complete response rate in a real-world study of 281 heavily pretreated Chinese patients with relapsed or refractory plasma cell neoplasms, data presented at the 2026 International Myeloma Society Annual Meeting show.

Real-world cohort skews higher-risk than pivotal trial population

The multicenter study tracked patients treated since FUCASO's June 2023 launch across China. Median age was 61 years, with 18.7% aged 70 or older, and patients had received a median of four prior therapy lines, up to 12. Prior anti-CD38 exposure reached 84.0%, 27.4% were penta-exposed, and 46.9% had undergone autologous stem cell transplantation. High-risk cytogenetic abnormalities affected 82.4% of patients, 50.5% were ISS stage III, 7.8% had plasma cell leukemia, and 47.0% presented extramedullary disease.

STEMREGEN Ranks No. 332 on Inc. 5000 With 1,017% Growth

Image
STEMREGEN Ranks No. 332 on Inc. 5000 With 1,017% Growth

Whitefish, Mont. – September 26, 2026 -- STEMREGEN, a maker of science-backed stem cell supplements, has landed at No. 332 on the 2026 Inc. 5000 list after posting 1,017% revenue growth over three years, far outpacing the list's 130% median.

Company secures third straight Inc. 5000 ranking as growth trajectory accelerates

STEMREGEN previously ranked No. 265 in 2025 and No. 1,765 in 2024, marking three consecutive years on the annual list of America's fastest-growing private companies. The 2026 ranking measures revenue growth from 2022 through 2025.

MAYPHARM Launches HYALMASS AQUATOX, a Five-Active Aesthetic Formula

Image
MAYPHARM Launches HYALMASS AQUATOX, a Five-Active Aesthetic Formula

Seoul – September 26, 2026 -- MAYPHARM has announced the upcoming launch of HYALMASS AQUATOX, a new aesthetic formulation combining five high-interest active ingredients into a single product for the global cosmeceutical market.

MAYPHARM combines five actives into one formulation to meet multifunctional demand

The new product integrates PDRN, Exosomes, Botulinum Peptide, GHK-Cu, and Succinic Acid in one advanced skin solution. Botulinum Peptide is designed to support a smoother skin appearance, while GHK-Cu is studied for skin conditioning and regeneration. Succinic Acid is positioned for antioxidant activity, PDRN for skin regeneration and recovery, and Exosomes for advanced rejuvenation approaches.

MSE Gives MedStar Health $1.1M for D.C. Maternal, Pediatric Care

Image
MSE Gives MedStar Health $1.1M for D.C. Maternal, Pediatric Care

Washington, D.C. – September 26, 2026 -- Monumental Sports & Entertainment (MSE) has donated $1.1 million to MedStar Health, extending a five-year philanthropic commitment first pledged in 2024 to fund maternal, infant and pediatric care programs across Washington, D.C.

MSE and MedStar Health extend a five-year funding pledge into its third year

The gift continues annual support MSE committed in 2024 to expand access to specialized health services for birthing mothers and children in the District. Since 2019, MSE and The Leonsis Family have contributed more than $13 million to MedStar Health initiatives, including pediatric community health, COVID-19 response and sports medicine programs.

N95 Mask Market to Triple to $11.08B by 2034 on Safety Rules

Image
N95 Mask Market to Triple to $11.08B by 2034 on Safety Rules

Pune – – September 26, 2026 -- The global N95 mask market is projected to grow from $3.27 billion in 2025 to $11.08 billion by 2034, a 14.52% compound annual growth rate, according to Maximize Market Research.

North America dominates as major respirator makers expand capacity

North America held the largest regional share in 2025, driven by hospital demand, workplace safety mandates, and infection-control requirements. Manufacturers including 3M, Honeywell, Moldex-Metric, Cardinal Health, and Medline Industries maintain significant production presence in the region, supporting its lead position through continued investment in respiratory-protection capacity.

AI Clinical Trials Market to Hit $7.32B by 2034, 15.5% CAGR

Image
AI Clinical Trials Market to Hit $7.32B by 2034, 15.5% CAGR

Pune, India – September 26, 2026 -- The global AI in Clinical Trials Market is set to more than triple from USD 2 billion in 2025 to USD 7.32 billion by 2034, expanding at a 15.5% compound annual growth rate, according to Maximize Market Research.

Pharmaceutical firms accelerate AI adoption to cut trial delays

Pharmaceutical and biotechnology companies, along with contract research organizations, hospitals and research institutes, are deploying machine learning, natural language processing and deep learning to speed patient screening, cohort selection, trial design and large-scale data analysis. These tools are applied across Phase I, Phase II and Phase III trials for patient recruitment, safety monitoring, drug discovery and personalized medicine.

Clinical Trials Market to Hit $99.4B by 2034 on AI, Decentralized Trial Growth

Image
Clinical Trials Market to Hit $99.4B by 2034 on AI, Decentralized Trial Growth

Pune – September 26, 2026 -- The global clinical trials market reached USD 58.19 billion in 2025 and is forecast to grow at a 6.13% compound annual rate through 2034, reaching USD 99.4 billion, according to Maximize Market Research.

North America retains dominant share on trial infrastructure and R&D spend

North America leads global trial activity, underpinned by extensive pharmaceutical and biotechnology infrastructure, significant cancer research burden, and the presence of major contract research organizations. The United States drives the bulk of regional Phase I-IV trial volume, while Canada contributes through government investment in trial infrastructure. Europe holds a substantial share as well, with the UK, France, Germany, Italy, Spain, Sweden and Austria supporting research across oncology, cardiovascular disease, CNS conditions, diabetes, obesity and autoimmune disorders.

Dietary Supplements Market to Hit $324.88B by 2034, Says MMR

Image
Dietary Supplements Market to Hit $324.88B by 2034, Says MMR

Pune, India – September 26, 2026 -- The global dietary supplements market was valued at USD 186.36 billion in 2025 and is forecast to reach USD 324.88 billion by 2034, expanding at a compound annual growth rate of 6.37% between 2026 and 2034, according to a new report from Maximize Market Research.

North America dominates supplement demand on preventive healthcare spending

North America leads the global market, driven by high consumer spending on health and wellness, strong preventive healthcare awareness, and regulatory clarity that supports major dietary supplement manufacturers. The United States remains the largest contributor within the region, with strong uptake of vitamins, minerals, herbal supplements, probiotics, and sports nutrition products.